Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg Nine-Month Period […]